Emerging China Compliance Issues Warrant Closer Watch: Experts
Executive Summary
A new dual receipting system, a potential registry for sales reps, and rules over false advertisements and promotion are just some of the many and growing challenges pressuring pharna corporate compliance officers in China, experts attending a recent conference said.
You may also be interested in...
The ‘Sanming Model’: Bad Omen Or Hope For Pharma In China?
Pharma executives in China may soon get an earful of the name Sanming, as the populist healthcare reform model that began at the small city in Fujian is rolled out nationwide and impacts profoundly how drugs are tendered, priced and distributed.
Nike’s Importation Fine Serves As A Lesson For Drug Firms In China
Beijing issued Nike a RMB 4.87 million fine for using double standards for an imported product in China, prompting legal and industry watchers to warn multinational companies to keep prices competitive or they could find themselves under tighter scrutiny.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.